Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease

Review

doi: 10.1016/j.npep.2021.102196.

Online ahead of print.

Deepthi Rapaka¹, Veera Raghavulu Bitra², Siva Reddy Challa³, Paul C Adiukwu²

Affiliations

PMID: 34508923
DOI: 10.1016/j.npep.2021.102196

Abstract

Alzheimer’s disease (AD) isaprogressive neurodegenerative disorder characterized by chronic inflammation due to the presence of neurotoxic Aβ and tau proteins. Increased microglial activation and inflated immune response are the other factors to be considered in AD pathology. Microglial cells own biochemical machinery that synthesizes and release endocannabinoids. The exploitation of therapeutic actions of endocannabinoid system has newly emerged in the field of Alzheimer’s disease. The activation of cannabinoid receptors/ cannabinoid system modulates inflammatory responses. This review assesses the association between the microglial endocannabinoid system and neuroinflammation in AD. The data supporting the anti-inflammatory role of pharmacological agents modulating cannabinoid system are also reviewed.

Keywords: Alzheimer’s disease, CB(1)R, CB(2)R, Endocannabinoid, Microglia, Neuroinflammation

Similar articles

Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease.

Mulder J, Zilberter M, Pasquaré SJ, Alpár A, Schulte G, Ferreira SG, Köfalvi A, Martín-Moreno AM, Keimpema E, Tanila H, Watanabe M, Mackie K, Hortobágyi T, de Ceballos ML, Harkany T.Brain. 2011 Apr;134(Pt 4):1041-60. doi: 10.1093/brain/awr046.PMID: 21459826 Free PMC article.
Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease.

Streit WJ, Braak H, Xue QS, Bechmann I.Acta Neuropathol. 2009 Oct;118(4):475-85. doi: 10.1007/s00401-009-0556-6. Epub 2009 Jun 10.PMID: 19513731 Free PMC article.
Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB₁ and CB₂ receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia.

Navarro G, Borroto-Escuela D, Angelats E, Etayo Í, Reyes-Resina I, Pulido-Salgado M, Rodríguez-Pérez AI, Canela EI, Saura J, Lanciego JL, Labandeira-García JL, Saura CA, Fuxe K, Franco R.Brain Behav Immun. 2018 Jan;67:139-151. doi: 10.1016/j.bbi.2017.08.015. Epub 2017 Aug 24.PMID: 28843453
Microglial priming in Alzheimer’s disease.

Li JW, Zong Y, Cao XP, Tan L, Tan L.Ann Transl Med. 2018 May;6(10):176. doi: 10.21037/atm.2018.04.22.PMID: 29951498 Free PMC article. Review.
Chronic stress as a risk factor for Alzheimer’s disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress.

Bisht K, Sharma K, Tremblay MÈ.Neurobiol Stress. 2018 May 19;9:9-21. doi: 10.1016/j.ynstr.2018.05.003. eCollection 2018 Nov.PMID: 29992181 Free PMC article. Review.